Pharmaceutical giant Bristol-Myers Squibb (BMY) has broken out to a new high for the move up. Traders should be long from our March 7 review, where we wrote that "Traders could go long BMY at current levels risking to $66. Our price targets are $89 and then $95. Fingers crossed we have it right this time."
More from Investing
Has this recent very powerful rally created a supply of underinvested bulls who are anxious to buy pullbacks and dips?
Let's perform an intermarket correlation check, and see how commodities moved vs. themselves and the buck -- and what to expect next.
SIX gaps lower and a new decline has been set in motion after earnings. Let's check the charts.
The Strive U.S. Energy exchange-traded fund is billed as an anti-ESG ETF. Let's see how it stacks up against the similar Energy Select SPDR Fund.